Incyte (INCY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Incyte Revenue Highlights

Latest Revenue (Y)

$3.70B

Latest Revenue (Q)

$962.99M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Incyte Revenue by Period

Incyte Revenue by Year

Date	Revenue	Change
2023-12-31	$3.70B	8.87%
2022-12-31	$3.39B	13.67%
2021-12-31	$2.99B	11.98%
2020-12-31	$2.67B	23.53%
2019-12-31	$2.16B	14.71%
2018-12-31	$1.88B	22.50%
2017-12-31	$1.54B	38.93%
2016-12-31	$1.11B	46.70%
2015-12-31	$753.75M	47.36%
2014-12-31	$511.50M	44.10%
2013-12-31	$354.95M	19.49%
2012-12-31	$297.06M	214.50%
2011-12-31	$94.45M	-44.40%
2010-12-31	$169.88M	1733.55%
2009-12-31	$9.27M	136.41%
2008-12-31	$3.92M	-88.62%
2007-12-31	$34.44M	24.59%
2006-12-31	$27.64M	252.32%
2005-12-31	$7.85M	-44.54%
2004-12-31	$14.15M	-69.96%
2003-12-31	$47.09M	-53.66%
2002-12-31	$101.61M	-53.66%
2001-12-31	$219.26M	12.92%
2000-12-31	$194.17M	23.67%
1999-12-31	$157.00M	16.47%
1998-12-31	$134.80M	52.49%
1997-12-31	$88.40M	111.48%
1996-12-31	$41.80M	242.62%
1995-12-31	$12.20M	6000.00%
1994-12-31	$200.00K	-33.33%
1993-12-31	$300.00K	-

Incyte generated $3.70B in revenue during NA 2023, up 8.87% compared to the previous quarter, and up 196.38% compared to the same period a year ago.

Incyte Revenue by Quarter

Date	Revenue	Change
2024-09-30	$962.99M	-7.74%
2024-06-30	$1.04B	18.49%
2024-03-31	$880.89M	-13.07%
2023-12-31	$1.01B	10.26%
2023-09-30	$919.02M	-3.73%
2023-06-30	$954.61M	18.05%
2023-03-31	$808.67M	-12.74%
2022-12-31	$926.70M	12.56%
2022-09-30	$823.30M	-9.67%
2022-06-30	$911.40M	24.30%
2022-03-31	$733.24M	-15.02%
2021-12-31	$862.85M	6.13%
2021-09-30	$812.99M	15.20%
2021-06-30	$705.71M	16.70%
2021-03-31	$604.72M	-23.41%
2020-12-31	$789.51M	27.21%
2020-09-30	$620.64M	-9.80%
2020-06-30	$688.04M	21.03%
2020-03-31	$568.51M	-1.88%
2019-12-31	$579.39M	5.04%
2019-09-30	$551.58M	4.09%
2019-06-30	$529.93M	6.44%
2019-03-31	$497.86M	-5.78%
2018-12-31	$528.40M	17.51%
2018-09-30	$449.68M	-13.77%
2018-06-30	$521.52M	36.42%
2018-03-31	$382.28M	-13.93%
2017-12-31	$444.16M	16.41%
2017-09-30	$381.53M	16.88%
2017-06-30	$326.44M	-15.01%
2017-03-31	$384.08M	17.64%
2016-12-31	$326.50M	21.16%
2016-09-30	$269.47M	9.41%
2016-06-30	$246.29M	-6.52%
2016-03-31	$263.46M	8.03%
2015-12-31	$243.88M	29.99%
2015-09-30	$187.61M	15.11%
2015-06-30	$162.98M	2.33%
2015-03-31	$159.28M	28.48%
2014-12-31	$123.97M	-37.43%
2014-09-30	$198.15M	98.98%
2014-06-30	$99.58M	10.90%
2014-03-31	$89.79M	-7.50%
2013-12-31	$97.07M	14.04%
2013-09-30	$85.12M	-16.28%
2013-06-30	$101.67M	43.05%
2013-03-31	$71.08M	-37.57%
2012-12-31	$113.85M	88.20%
2012-09-30	$60.49M	-30.10%
2012-06-30	$86.54M	139.21%
2012-03-31	$36.18M	25.23%
2011-12-31	$28.89M	72.15%
2011-09-30	$16.78M	-0.17%
2011-06-30	$16.81M	-47.42%
2011-03-31	$31.97M	-62.77%
2010-12-31	$85.87M	408.95%
2010-09-30	$16.87M	-66.15%
2010-06-30	$49.85M	188.33%
2010-03-31	$17.29M	151.79%
2009-12-31	$6.87M	631.20%
2009-09-30	$939.00K	19.01%
2009-06-30	$789.00K	17.59%
2009-03-31	$671.00K	-28.46%
2008-12-31	$938.00K	-11.59%
2008-09-30	$1.06M	72.80%
2008-06-30	$614.00K	-53.02%
2008-03-31	$1.31M	-

Incyte generated $962.99M in revenue during Q3 2024, up -7.74% compared to the previous quarter, and up 100.88% compared to the same period a year ago.

Incyte Revenue Breakdown

Incyte Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Milestone And Contract Revenue	$165.00M	$205.00M	$77.50M	$180.00M	-
Olumiant Royalty	$134.55M	$110.92M	$80.42M	-	-
OPZELURA	$128.74M	$4.91M	-	-	-
Royalty	$482.74M	$392.97M	$306.34M	$234.78M	-
PEMAZYRE Royalty Revenues	$84.65M	-	-	-	-
Tabrecta Royalty Revenues	$15.41M	$4.14M	-	-	-
Milestone and contract revenues	$165.00M	$95.00M	-	-	-
J A K A F I	$2.74B	-	-	-	-
M I N J U V I	$19.65M	-	-	-	-
Product	$2.75B	$2.07B	$1.77B	$1.47B	-
I C L U S I G	$105.84M	$105.00M	$89.95M	-	-
Product revenues, net	-	$2.32B	-	-	-
ICLUSIG	-	$4.67M	-	-	-
JAKAVI Royalty Revenues	-	$337.99M	-	-	-
MINJUVI	-	$68.53M	-	-	-
OLUMIANT Royalty Revenues	-	$220.88M	-	-	-
PEMAZYRE	-	$109.39M	-	-	-
Product royalty revenues	-	$569.25M	-	-	-
TABRECTA Royalty Revenues	-	$10.39M	-	-	-
Jakavi Royalty Revenues	-	-	$277.90M	$225.91M	-
Pemazyre	-	-	$25.88M	-	-
Product And Service Other	-	-	-	-	$203.00K

Incyte's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (40.46%), J A K A F I (40.37%), Royalty (7.11%), Milestone And Contract Revenue (2.43%), Milestone and contract revenues (2.43%), Olumiant Royalty (1.98%), OPZELURA (1.90%), I C L U S I G (1.56%), PEMAZYRE Royalty Revenues (1.25%), M I N J U V I (0.29%), and Tabrecta Royalty Revenues (0.23%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Tabrecta Royalty Revenues	$5.93M	$5.30M	$5.23M	$2.75M	$2.48M	$2.05M	$2.00M	$1.44M	$706.00K	-	-	-	-	-	-	-	-	-	-	-
ZYNYZ	$694.00K	$651.00K	$467.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
PEMAZYRE Royalty Revenues	$21.07M	$21.14M	$18.22M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
OPZELURA	$139.27M	$121.69M	$85.72M	$91.84M	$80.23M	$56.55M	$38.14M	$16.56M	$12.75M	-	-	-	-	-	-	-	-	-	-	-
Olumiant Royalty	$34.80M	$31.70M	$30.59M	$86.57M	$36.05M	$32.26M	$31.00M	$28.65M	$25.83M	$25.45M	$23.60M	$21.64M	-	-	-	-	-	-	-	-
Milestone And Contract Revenue	$18.00M	-	$25.00M	$35.00M	$10.00M	$110.00M	-	$95.00M	-	$17.50M	-	-	-	-	-	-	-	-	-	-
M I N J U V I	$31.44M	$31.12M	$23.87M	$556.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
J A K A F I	$115.74M	$99.32M	$89.59M	$547.37M	$529.05M	$465.71M	$516.88M	$487.78M	$473.71M	$459.48M	$466.46M	$433.39M	-	-	-	-	-	-	-	-
I C L U S I G	$29.75M	$26.86M	$30.34M	$28.52M	$28.19M	$25.64M	$28.58M	$26.38M	$22.80M	$27.25M	$24.31M	$20.61M	-	-	-	-	-	-	-	-
ICLUSIG	-	-	$30.34M	$27.72M	$29.09M	$27.68M	$25.93M	$26.22M	$26.07M	$-77.69M	-	-	-	-	-	-	-	-	-	-
JAKAVI Royalty Revenues	-	-	$89.59M	$96.55M	$90.45M	$76.69M	$85.81M	$83.71M	$70.87M	$95.70M	-	-	-	-	-	-	-	-	-	-
Milestone and contract revenues	-	-	$25.00M	-	$5.00M	$50.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
OLUMIANT Royalty Revenues	-	-	$30.59M	$29.61M	$32.01M	$34.16M	$20.37M	$66.00M	-	-	-	-	-	-	-	-	-	-	-	-
PEMAZYRE	-	-	$17.68M	$18.94M	$21.57M	$22.48M	$23.41M	$18.98M	$18.03M	$60.47M	-	-	-	-	-	-	-	-	-	-
Product	-	-	$729.92M	$783.20M	$827.00M	$693.24M	$713.01M	$594.01M	$575.15M	$504.81M	$559.47M	$522.25M	$500.29M	$486.73M	$490.78M	$454.00M	-	-	-	-
Royalty	-	-	$125.97M	$130.83M	$127.61M	$115.44M	$110.29M	$183.97M	$120.56M	$99.91M	$120.04M	$98.39M	$92.75M	$81.78M	$88.61M	$80.08M	-	-	-	-
TABRECTA Royalty Revenues	-	-	$5.23M	$4.14M	$4.80M	$4.18M	$4.11M	$3.58M	$3.48M	$3.12M	-	-	-	-	-	-	-	-	-	-
MINJUVI	-	-	-	$8.35M	$13.16M	$6.56M	$5.93M	$4.41M	$4.50M	$67.97M	-	-	-	-	-	-	-	-	-	-
JAKAFI	-	-	-	$636.25M	$682.38M	$579.97M	$647.49M	$619.60M	$597.67M	$544.46M	$592.37M	-	-	-	-	-	-	-	-	-
Product royalty revenues	-	-	-	-	-	-	-	-	$117.55M	$122.41M	$164.81M	-	-	-	-	-	-	-	-	-
Product revenues, net	-	-	-	-	-	-	-	-	$663.85M	$605.82M	$648.04M	-	-	-	-	-	-	-	-	-
Pemazyre	-	-	-	-	-	-	-	-	-	-	-	$17.56M	$17.91M	$13.46M	$14.01M	$8.09M	$3.79M	-	-	-
Jakavi Royalty Revenues	-	-	-	-	-	-	-	-	-	-	-	$94.66M	$82.04M	$65.60M	$87.05M	$68.31M	$66.22M	$56.33M	$65.01M	$58.44M
Milestone Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Incyte's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: OPZELURA (35.11%), J A K A F I (29.18%), Olumiant Royalty (8.77%), M I N J U V I (7.93%), I C L U S I G (7.50%), PEMAZYRE Royalty Revenues (5.31%), Milestone And Contract Revenue (4.54%), Tabrecta Royalty Revenues (1.49%), and ZYNYZ (0.17%).

Incyte Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Europe	$147.00M	$124.10M	$105.00M	$90.00M	$79.90M
UNITED STATES	$3.20B	-	-	-	-
U.S.	-	$2.90B	-	-	-
U	-	-	$2.60B	$2.10B	$1.80B

Incyte's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (95.61%), and Europe (4.39%).

Quarterly Revenue by Country

Country	Dec 19	Dec 18
Non Us	$88.60M	$69.20M

Incyte's latest quarterly revenue breakdown by geography, as of Dec 19: Non Us (100.00%).

Incyte Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
INCY	Incyte	$3.70B	$962.99M
BGNE	BeiGene	$2.46B	$929.17M
BMRN	BioMarin Pharmaceutical	$2.42B	$733.87B
UTHR	United Therapeutics	$2.33B	$748.90M
ALNY	Alnylam Pharmaceuticals	$1.83B	$420.15M
SRPT	Sarepta Therapeutics	$1.24B	$362.93M
ARGX	argenx SE	$1.23B	$401.00M
IONS	Ionis Pharmaceuticals	$787.65M	$225.25M
ACAD	ACADIA Pharmaceuticals	$726.44M	$250.40M
HRMY	Harmony Biosciences	$582.02M	$186.04M
RARE	Ultragenyx Pharmaceutical	$434.25M	$147.03M
FOLD	Amicus Therapeutics	$399.36M	$141.52M
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
DNLI	Denali Therapeutics	$330.53M	-
AXSM	Axsome Therapeutics	$270.60M	$87.17M
ARWR	Arrowhead Pharmaceuticals	$3.55M	-

INCY Revenue FAQ

What is Incyte’s yearly revenue?

Incyte's yearly revenue for 2023 was $3.7B, representing an increase of 8.87% compared to 2022. The company's yearly revenue for 2022 was $3.39B, representing an increase of 13.67% compared to 2021. INCY's yearly revenue for 2021 was $2.99B, representing an increase of 11.98% compared to 2020.

What is Incyte’s quarterly revenue?

Incyte's quarterly revenue for Q3 2024 was $962.99M, a -7.74% decrease from the previous quarter (Q2 2024), and a 4.78% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.04B, a 18.49% increase from the previous quarter (Q1 2024), and a 9.34% increase year-over-year (Q2 2023). INCY's quarterly revenue for Q1 2024 was $880.89M, a -13.07% decrease from the previous quarter (Q4 2023), and a 8.93% increase year-over-year (Q1 2023).

What is Incyte’s revenue growth rate?

Incyte's revenue growth rate for the last 3 years (2021-2023) was 23.75%, and for the last 5 years (2019-2023) was 71.19%.

What are Incyte’s revenue streams?

Incyte's revenue streams in c 22 are Milestone And Contract Revenue, Olumiant Royalty, OPZELURA, Royalty, PEMAZYRE Royalty Revenues, Tabrecta Royalty Revenues, Milestone and contract revenues, J A K A F I, M I N J U V I, Product, and I C L U S I G. Milestone And Contract Revenue generated $165M in revenue, accounting 2.43% of the company's total revenue, down -19.51% year-over-year. Olumiant Royalty generated $134.55M in revenue, accounting 1.98% of the company's total revenue, up 21.30% year-over-year. OPZELURA generated $128.74M in revenue, accounting 1.90% of the company's total revenue, up 2521.89% year-over-year. Royalty generated $482.74M in revenue, accounting 7.11% of the company's total revenue, up 22.84% year-over-year. PEMAZYRE Royalty Revenues generated $84.65M in revenue, accounting 1.25% of the company's total revenue Tabrecta Royalty Revenues generated $15.41M in revenue, accounting 0.23% of the company's total revenue, up 271.89% year-over-year. Milestone and contract revenues generated $165M in revenue, accounting 2.43% of the company's total revenue, up 73.68% year-over-year. J A K A F I generated $2.74B in revenue, accounting 40.37% of the company's total revenue M I N J U V I generated $19.65M in revenue, accounting 0.29% of the company's total revenue Product generated $2.75B in revenue, accounting 40.46% of the company's total revenue, up 32.78% year-over-year. I C L U S I G generated $105.84M in revenue, accounting 1.56% of the company's total revenue, up 0.80% year-over-year.

What is Incyte’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Incyte was Product. This segment made a revenue of $2.75B, representing 40.46% of the company's total revenue.